200 related articles for article (PubMed ID: 23662183)
1. Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension.
Raina A; Coons JC; Kanwar M; Murali S; Sokos G; Benza RL
Pulm Circ; 2013 Jan; 3(1):116-20. PubMed ID: 23662183
[TBL] [Abstract][Full Text] [Related]
2. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
[TBL] [Abstract][Full Text] [Related]
3. Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension.
Pan IZ; Carey JR; Jacobs JA; Dechand J; Sessions JJ; Sorensen T; Penn BA; Mayeux JD; Hatton ND; Ryan JJ
Front Med (Lausanne); 2020; 7():81. PubMed ID: 32296704
[No Abstract] [Full Text] [Related]
4. Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension.
Preston IR; Feldman J; White J; Franco V; Ishizawar D; Burger C; Waxman AB; Hill NS
Pulm Circ; 2014 Sep; 4(3):456-61. PubMed ID: 25621159
[TBL] [Abstract][Full Text] [Related]
5. An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinil.
Rahaghi FF; Allen RP; Balasubramanian VP; Chakinala MM; Elwing JM; Feldman J; Leary PJ; Rischard F; Safdar Z; Sood N; Oudiz RJ
Pulm Pharmacol Ther; 2021 Feb; 66():101979. PubMed ID: 33259923
[TBL] [Abstract][Full Text] [Related]
6. Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
Ackerbauer KA; Tandon R
J Pharm Pract; 2018 Apr; 31(2):163-166. PubMed ID: 28464760
[TBL] [Abstract][Full Text] [Related]
7. Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension.
Ataya A; Somoracki A; Cope J; Alnuaimat H
Pulm Pharmacol Ther; 2016 Oct; 40():39-43. PubMed ID: 27470680
[TBL] [Abstract][Full Text] [Related]
8. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
Gessler T; Seeger W; Schmehl T
Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
10. Transitioning Parenteral or Inhaled Treprostinil to Oral Treprostinil Diolamine: Case Series and Review of the Literature.
Smith ZR; Kelly B; Awdish RL; Hegab S
J Pharm Pract; 2019 Oct; 32(5):599-604. PubMed ID: 29558853
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.
Krishnan U; Takatsuki S; Ivy DD; Kerstein J; Calderbank M; Coleman E; Rosenzweig EB
Am J Cardiol; 2012 Dec; 110(11):1704-9. PubMed ID: 22917554
[TBL] [Abstract][Full Text] [Related]
12. Real-world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting.
Balasubramanian VP; Safdar Z; Sketch MR; Broderick M; Nelsen AC; Lee D; Melendres-Groves L
Pulm Circ; 2022 Jan; 12(1):e12016. PubMed ID: 35506102
[TBL] [Abstract][Full Text] [Related]
13. A multicenter retrospective study of patients with pulmonary hypertension transitioned from inhaled to oral treprostinil.
Zwicke DL; Restrepo-Jaramillo R; Alnuaimat H; Gordon K; Broderick M; Edwards LD; Allmon A; Leary PJ
Pulm Circ; 2021; 11(1):2045894021998203. PubMed ID: 33738096
[TBL] [Abstract][Full Text] [Related]
14. Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension.
Ivy DD; Feinstein JA; Yung D; Mullen MP; Kirkpatrick EC; Hirsch R; Austin ED; Fineman J; Truong U; Solum D; Deng CQ; Hopper RK
Pulm Circ; 2019; 9(3):2045894019856471. PubMed ID: 31215336
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost.
Channick RN; Frantz RP; Kawut SM; Palevsky H; Tumuluri R; Sulica R; Lauto PO; Benton WW; de Boisblanc B
Pulm Circ; 2013 Apr; 3(2):381-8. PubMed ID: 24015339
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis.
Song C; Kunovszki P; Beaudet A
J Health Econ Outcomes Res; 2022; 9(1):151-160. PubMed ID: 35800882
[No Abstract] [Full Text] [Related]
17. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients transitioned from parenteral or inhaled prostacyclins: case series and treatment protocol.
Coons JC; Miller T; Simon MA; Ishizawar DC; Mathier MA
Pulm Circ; 2016 Mar; 6(1):132-5. PubMed ID: 27162621
[TBL] [Abstract][Full Text] [Related]
18. Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension.
Mouratoglou SA; Patsiala A; Feloukidis C; Karvounis H; Giannakoulas G
Int J Cardiol; 2020 May; 306():187-189. PubMed ID: 32115272
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.
de Jesus Perez VA; Rosenzweig E; Rubin LJ; Poch D; Bajwa A; Park M; Jain M; Bourge RC; Kudelko K; Spiekerkoetter E; Liu J; Hsi A; Zamanian RT
Am J Cardiol; 2012 Nov; 110(10):1546-50. PubMed ID: 22853986
[TBL] [Abstract][Full Text] [Related]
20. Different efficacy of inhaled and oral medications in pulmonary hypertension.
AbuHalimeh BJ; Parambil JG; Tonelli AR
Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
